Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Irene Y Cheung

Showing results (31-40 of 49) with videos related to

Pageof 5
Sort By:
Oncoimmunology|November 18, 2017
Phase I trial of anti-GD2 monoclonal antibody hu3F8 plus GM-CSF: Impact of body weight, immunogenicity and anti-GD2 response on pharmacokinetics and survivalIrene Y Cheung, Brian H Kushner, Shakeel Modak, et al.
Oncoimmunology|July 4, 2015
Prolonged progression-free survival after consolidating second or later remissions of neuroblastoma with Anti-G<sub>D2</sub> immunotherapy and isotretinoin: a prospective Phase II studyBrian H Kushner, Irina Ostrovnaya, Irene Y Cheung, et al.
Lung Cancer (Amsterdam, Netherlands)|May 22, 2009
Analysis of GD2/GM2 synthase mRNA as a biomarker for small cell lung cancerLin-Chi Chen, Andrew B Brown, Irene Y Cheung, et al.
Genes, Chromosomes & Cancer|June 6, 2014
Deep MicroRNA sequencing reveals downregulation of miR-29a in neuroblastoma central nervous system metastasisIrene Y Cheung, Thalia A Farazi, Irina Ostrovnaya, et al.
Cancers|December 24, 2021
Phase I Trial of Oral Yeast-Derived β-Glucan to Enhance Anti-GD2 Immunotherapy of Resistant High-Risk NeuroblastomaFiorella Iglesias Cardenas, Audrey Mauguen, Irene Y Cheung, et al.
JAMA Oncology|December 22, 2022
Effect of Oral β-Glucan on Antibody Response to Ganglioside Vaccine in Patients With High-Risk Neuroblastoma: A Phase 2 Randomized Clinical TrialIrene Y Cheung, Audrey Mauguen, Shakeel Modak, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 11, 2025
A Phase II Trial of Naxitamab plus Stepped-up Dosing of GM-CSF for Patients with High-Risk Neuroblastoma in First Complete RemissionBrian H Kushner, Shakeel Modak, Audrey Mauguen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 16, 2020
Survival Impact of Anti-GD2 Antibody Response in a Phase II Ganglioside Vaccine Trial Among Patients With High-Risk Neuroblastoma With Prior Disease ProgressionIrene Y Cheung, Nai-Kong V Cheung, Shakeel Modak, et al.
FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology|August 23, 2011
MYCN and MYC regulate tumor proliferation and tumorigenesis directly through BMI1 in human neuroblastomasRuimin Huang, Nai-Kong V Cheung, Jelena Vider, et al.
International Journal of Cancer|March 20, 2014
Key role for myeloid cells: phase II results of anti-G(D2) antibody 3F8 plus granulocyte-macrophage colony-stimulating factor for chemoresistant osteomedullary neuroblastomaNai-Kong V Cheung, Irene Y Cheung, Kim Kramer, et al.
Pageof 5

Showing results (31-40 of 49) with videos related to

Sort By:
Pageof 5
Oncoimmunology|November 18, 2017
Phase I trial of anti-GD2 monoclonal antibody hu3F8 plus GM-CSF: Impact of body weight, immunogenicity and anti-GD2 response on pharmacokinetics and survivalIrene Y Cheung, Brian H Kushner, Shakeel Modak, et al.
Oncoimmunology|July 4, 2015
Prolonged progression-free survival after consolidating second or later remissions of neuroblastoma with Anti-G<sub>D2</sub> immunotherapy and isotretinoin: a prospective Phase II studyBrian H Kushner, Irina Ostrovnaya, Irene Y Cheung, et al.
Lung Cancer (Amsterdam, Netherlands)|May 22, 2009
Analysis of GD2/GM2 synthase mRNA as a biomarker for small cell lung cancerLin-Chi Chen, Andrew B Brown, Irene Y Cheung, et al.
Genes, Chromosomes & Cancer|June 6, 2014
Deep MicroRNA sequencing reveals downregulation of miR-29a in neuroblastoma central nervous system metastasisIrene Y Cheung, Thalia A Farazi, Irina Ostrovnaya, et al.
Cancers|December 24, 2021
Phase I Trial of Oral Yeast-Derived β-Glucan to Enhance Anti-GD2 Immunotherapy of Resistant High-Risk NeuroblastomaFiorella Iglesias Cardenas, Audrey Mauguen, Irene Y Cheung, et al.
JAMA Oncology|December 22, 2022
Effect of Oral β-Glucan on Antibody Response to Ganglioside Vaccine in Patients With High-Risk Neuroblastoma: A Phase 2 Randomized Clinical TrialIrene Y Cheung, Audrey Mauguen, Shakeel Modak, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 11, 2025
A Phase II Trial of Naxitamab plus Stepped-up Dosing of GM-CSF for Patients with High-Risk Neuroblastoma in First Complete RemissionBrian H Kushner, Shakeel Modak, Audrey Mauguen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 16, 2020
Survival Impact of Anti-GD2 Antibody Response in a Phase II Ganglioside Vaccine Trial Among Patients With High-Risk Neuroblastoma With Prior Disease ProgressionIrene Y Cheung, Nai-Kong V Cheung, Shakeel Modak, et al.
FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology|August 23, 2011
MYCN and MYC regulate tumor proliferation and tumorigenesis directly through BMI1 in human neuroblastomasRuimin Huang, Nai-Kong V Cheung, Jelena Vider, et al.
International Journal of Cancer|March 20, 2014
Key role for myeloid cells: phase II results of anti-G(D2) antibody 3F8 plus granulocyte-macrophage colony-stimulating factor for chemoresistant osteomedullary neuroblastomaNai-Kong V Cheung, Irene Y Cheung, Kim Kramer, et al.
Pageof 5